Turk Ilac Ve Serum Sanayi Anonim Sirketi Valuation

Is TRILC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TRILC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TRILC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TRILC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRILC?

Key metric: As TRILC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TRILC. This is calculated by dividing TRILC's market cap by their current earnings.
What is TRILC's PE Ratio?
PE Ratio	12x
Earnings	₺256.36m
Market Cap	₺3.08b

TRILC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.8x
Enterprise Value/EBITDA	9.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does TRILC's PE Ratio compare to its peers?

The above table shows the PE ratio for TRILC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	24.3x
DEVA Deva Holding	4.4x	n/a	₺14.0b
GENIL Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi	56.7x	n/a	₺31.7b
239 Pak Fah Yeow International	7.9x	n/a	HK$766.6m
8432 TSH Biopharm	28.1x	n/a	NT$2.5b
TRILC Turk Ilac Ve Serum Sanayi Anonim Sirketi	12x	n/a	₺3.1b

Price-To-Earnings vs Peers: TRILC is good value based on its Price-To-Earnings Ratio (12x) compared to the peer average (24.3x).

Price to Earnings Ratio vs Industry

How does TRILC's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

12 Companies	Price / Earnings	Estimated Growth	Market Cap

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: TRILC is good value based on its Price-To-Earnings Ratio (12x) compared to the Asian Pharmaceuticals industry average (24.1x).

Price to Earnings Ratio vs Fair Ratio

What is TRILC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRILC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	12x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate TRILC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.